Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 18%
Sell 9%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is poised for long-term success with their best-in-class technology and strong management execution, as evidenced by their record domestic Hydros sales and impressive procedure growth. The recent commercial initiatives implemented by newly appointed CEO Larry Wood are likely temporary headwinds, and the company's heavily discounted valuation and upcoming Investor Day provide potential for the stock to outperform.

Bears say

PROCEPT BioRobotics is currently facing several headwinds, including a recent voluntary field action and pricing pressure, which could impact its sales and overall financial performance. Additionally, increased competition in the BPH market could pose a threat to the company's sales and market position. These challenges, coupled with a recent reduction in revenue guidance, suggest a negative outlook for PROCEPT BioRobotics's stock.

PRCT has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 11 analysts, PRCT has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.